Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves 　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry

CONCLUSIONS: Approximately 30% of patients with AF and BPV replacement were treated with DOAC. The risks of major bleeding and stroke or systemic embolism were similar between warfarin- and DOAC-treated patients with AF who had BPV replacement. Treatment with DOACs could be an alternative to warfarin in this population.PMID:34719560 | DOI:10.1253/circj.CJ-21-0564

Source: Circulation Journal - November 1, 2021 Category: Cardiology Authors: Chisato Izumi Makoto Miyake Tomoyuki Fujita Tadaaki Koyama Hidekazu Tanaka Kenji Ando Tatsuhiko Komiya Masaki Izumo Hiroya Kawai Kiyoyuki Eishi Kiyoshi Yoshida Takeshi Kimura Ryuzo Nawada Tomohiro Sakamoto Yoshisato Shibata Toshihiro Fukui Kenji Minatoya Source Type: research